BR112023006274A2 - Proteína de fusão útil para vacinação contra rotavírus - Google Patents
Proteína de fusão útil para vacinação contra rotavírusInfo
- Publication number
- BR112023006274A2 BR112023006274A2 BR112023006274A BR112023006274A BR112023006274A2 BR 112023006274 A2 BR112023006274 A2 BR 112023006274A2 BR 112023006274 A BR112023006274 A BR 112023006274A BR 112023006274 A BR112023006274 A BR 112023006274A BR 112023006274 A2 BR112023006274 A2 BR 112023006274A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- rotavirus
- vaccination against
- fragment
- protein useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
PROTEÍNA DE FUSÃO ÚTIL PARA VACINAÇÃO CONTRA ROTAVÍRUS. A presente invenção refere-se a polipeptídeos construídos de forma recombinante úteis para preparar vacinas, em particular, para reduzir um ou mais de sinais clínicos causados por uma infecção por rotavírus. Mais especificamente, a presente invenção é dirigida a uma proteína de fusão c ompreendendo na direção N- para C-terminal (i) um fragmento imunogênico de uma proteína VP8 do rotavírus e (ii) um fragmento Fc de imunoglobulina tal como, por exemplo, um fragmento Fc de IgG, em que a referida proteína de fusão é utilizável em um método de redução de um ou mais de sinais clínicos, mortalidade ou excreção fecal causada(os) por uma infecção por rotavírus em suínos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20200161 | 2020-10-05 | ||
PCT/US2021/071701 WO2022076979A1 (en) | 2020-10-05 | 2021-10-04 | Fusion protein useful for vaccination against rotavirus |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023006274A2 true BR112023006274A2 (pt) | 2023-05-09 |
Family
ID=72752390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023006274A BR112023006274A2 (pt) | 2020-10-05 | 2021-10-04 | Proteína de fusão útil para vacinação contra rotavírus |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220160866A1 (pt) |
EP (1) | EP4225776A1 (pt) |
JP (1) | JP2023544396A (pt) |
KR (1) | KR20230082653A (pt) |
CN (1) | CN116438195A (pt) |
AU (1) | AU2021356630A1 (pt) |
BR (1) | BR112023006274A2 (pt) |
CA (1) | CA3195910A1 (pt) |
CL (1) | CL2023000836A1 (pt) |
CO (1) | CO2023003544A2 (pt) |
MX (1) | MX2023004006A (pt) |
TW (1) | TW202229314A (pt) |
WO (1) | WO2022076979A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240050555A1 (en) * | 2022-04-05 | 2024-02-15 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition useful for vaccination against rotavirus |
CN114875047A (zh) * | 2022-05-27 | 2022-08-09 | 江苏三仪生物工程有限公司 | 一种优化的猪轮状病毒外衣壳蛋白vp4的重组表达及应用 |
CN114957489B (zh) * | 2022-06-20 | 2023-11-21 | 甘肃省畜牧兽医研究所 | 一种猪轮状病毒重组蛋白及其应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US382425A (en) | 1888-05-08 | Brandt | ||
US920197A (en) | 1906-04-25 | 1909-05-04 | Benjamin Siegel | Garment-display rack. |
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1990001543A1 (fr) | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
EP0465529B1 (en) | 1989-03-21 | 1998-04-29 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
JP3602530B2 (ja) | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
EP0620277A1 (en) | 1993-03-18 | 1994-10-19 | Merck & Co. Inc. | Nucleic acid pharmaceuticals |
FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
ES2348013T3 (es) | 1994-01-27 | 2010-11-26 | University Of Massachusetts Medical Center | Inmunización por inoculación de una unidad de transcripción de adn. |
JP3911010B2 (ja) | 1994-04-29 | 2007-05-09 | イムノ・アクテイエンゲゼルシヤフト | 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス |
AU711702B2 (en) | 1995-03-23 | 1999-10-21 | Cambridge University Technical Services Limited | Vectors for gene delivery |
WO1998000166A1 (en) | 1996-07-03 | 1998-01-08 | Merial, Inc. | Recombinant canine adenovirus (cav) containing exogenous dna |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
US6187319B1 (en) * | 1998-06-01 | 2001-02-13 | University Of Massachusetts | Cross-protective rotavirus vaccine |
WO2011032256A1 (en) | 2009-09-17 | 2011-03-24 | Digifonica (International) Limited | Uninterrupted transmission of internet protocol transmissions during endpoint changes |
-
2021
- 2021-10-04 AU AU2021356630A patent/AU2021356630A1/en active Pending
- 2021-10-04 EP EP21794074.1A patent/EP4225776A1/en active Pending
- 2021-10-04 CN CN202180068147.2A patent/CN116438195A/zh active Pending
- 2021-10-04 CA CA3195910A patent/CA3195910A1/en active Pending
- 2021-10-04 TW TW110136858A patent/TW202229314A/zh unknown
- 2021-10-04 KR KR1020237015073A patent/KR20230082653A/ko unknown
- 2021-10-04 WO PCT/US2021/071701 patent/WO2022076979A1/en unknown
- 2021-10-04 JP JP2023520375A patent/JP2023544396A/ja active Pending
- 2021-10-04 BR BR112023006274A patent/BR112023006274A2/pt unknown
- 2021-10-04 US US17/493,269 patent/US20220160866A1/en active Pending
- 2021-10-04 MX MX2023004006A patent/MX2023004006A/es unknown
-
2023
- 2023-03-22 CO CONC2023/0003544A patent/CO2023003544A2/es unknown
- 2023-03-23 CL CL2023000836A patent/CL2023000836A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202229314A (zh) | 2022-08-01 |
KR20230082653A (ko) | 2023-06-08 |
CL2023000836A1 (es) | 2023-12-01 |
JP2023544396A (ja) | 2023-10-23 |
EP4225776A1 (en) | 2023-08-16 |
WO2022076979A1 (en) | 2022-04-14 |
US20220160866A1 (en) | 2022-05-26 |
CN116438195A (zh) | 2023-07-14 |
CA3195910A1 (en) | 2022-04-14 |
CO2023003544A2 (es) | 2023-06-30 |
AU2021356630A1 (en) | 2023-06-08 |
MX2023004006A (es) | 2023-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023006274A2 (pt) | Proteína de fusão útil para vacinação contra rotavírus | |
PE20061398A1 (es) | Vacuna de toxoide de c. perfringens alfa | |
Singh et al. | A Plasmodium falciparum 48/45 single epitope R0. 6C subunit protein elicits high levels of transmission blocking antibodies | |
BR112015023105A2 (pt) | construto de imunógeno de peptídeo a?, composições, anticorpo e usos de um construto ou combinação de imunógeno de peptídeo a? | |
PE20240825A1 (es) | Anticuerpos anti-c5 y metodos de uso | |
AR078423A1 (es) | Vacunas dirigidas a las celulas de langerhans | |
DK1968632T3 (da) | Forbedret influenzavaccine | |
BRPI1015917A2 (pt) | antígenos de rsv recombinantes. | |
BR112016019525A2 (pt) | construções de proteína uspa2 e seu uso | |
RU2020119271A (ru) | Вакцина для защиты от streptococcus suis | |
BR112015022617A2 (pt) | polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável | |
AU2010303568A1 (en) | Immunopotentiator-linked oligomeric influenza immunogenic compositions | |
BR112017001966A2 (pt) | ?método para produzir variantes com um fc com sialilação melhorada? | |
BR112016028418A2 (pt) | composição de adjuvante, vacina, anticorpo agonista cd40 ou uma parte desse, composição farmacêutica, construto, célula, e, método de mapeamento de epítopo de um polipeptídeo | |
BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
CL2021002727A1 (es) | Vacuna con subunidades del vfpc | |
BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
PE20081687A1 (es) | Proteina de fusion | |
CN105408347A (zh) | 寡聚流感免疫原性组合物 | |
BR112015023402A2 (pt) | Proteínas sintéticas de automontagem | |
BR112013009588A2 (pt) | vacinógeno ospc quimérico polivalente e antígeno para diagnóstico | |
BR112018009653A2 (pt) | produção de proteínas recombinantes n-deglicosiladas in vivo por co-expressão com endo h | |
BR112022011422A2 (pt) | Imunógenos para vírus da caxumba e do sarampo e seus usos | |
BR112021024176A2 (pt) | Anticorpos anti-angpt2 | |
WO2023194913A8 (en) | Immunogenic composition useful for vaccination against rotavirus |